Investment Considerations CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP)”
| Symbol | Release | Time | Source |
|---|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} | {{ release.source }} |
SmallCapRelations is part of the IBN (InvestorBrandNetwork).